Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792727 | 0.91 | ALDH1A1 (1.00) | ALDH1A1LMNAGAAKDM4EKAT6A | |
| SCHEMBL7973186 | 0.89 | ALDH1A1 (0.90) | ALDH1A1NPY1RNPY5RTBXA2R | |
| SCHEMBL7371174 | 0.87 | ALDH1A1 (0.68) | ALDH1A1LMNAGAAKAT6ASMN1; SMN2 | |
| SCHEMBL6438335 | 0.84 | ALDH1A1 (0.69) | ALDH1A1GAAKDM4EKAT6ACYP19A1 | |
| SCHEMBL16053212 | 0.83 | ALDH1A1 (0.67) | ALDH1A1LMNAGAAKAT6ASMN1; SMN2 | |
| SCHEMBL1200801 | 0.82 | ALDH1A1 (0.75) | ALDH1A1LMNAGAAKDM4ENPSR1 | |
| SCHEMBL565677 | 0.82 | ALDH1A1 (0.66) | ALDH1A1LMNAGAAKAT6ASMN1; SMN2 | |
| SCHEMBL6791372 | 0.82 | ALDH1A1 (0.77) | ALDH1A1KAT6ATBXA2R | |
| SCHEMBL3147274 | 0.81 | ALDH1A1 (0.73) | ALDH1A1LMNAGAASMN1; SMN2NPY1R | |
| SCHEMBL393890 | 0.81 | ALDH1A1 (0.76) | ALDH1A1LMNAGAAKAT6ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032291-A1 | Compstatin Analogs With Improved Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-02-04 | — | — | US | disclosed |
| US-10745442-B2 | Compstatin analogs with improved pharmacokinetic properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190077834-A1 | Compstatin Analogs With Improved Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-03-14 | — | — | US | disclosed |
| US-10174079-B2 | Compstatin analogs with improved pharmacokinetic properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170247413-A1 | COMPSTATIN ANALOGS WITH IMPROVED PHARMACOKINETIC PROPERTIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247413-A1 | COMPSTATIN ANALOGS WITH IMPROVED PHARMACOKINETIC PROPERTIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-06-22 | — | — | US | disclosed |
| US-9630992-B2 | Compstatin analogs with improved pharmacokinetic properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630992-B2 | Compstatin analogs with improved pharmacokinetic properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-04-25 | — | — | US | disclosed |
| US-9371365-B2 | Modified compstatin with peptide backbone and C-terminal modifications | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-06-21 | — | — | US | disclosed |
| US-20120178694-A1 | Modified Compstatin With Peptide Backbone And C-Terminal Modifications | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2012-07-12 | — | — | US | disclosed |
| US-20120178694-A1 | Modified Compstatin With Peptide Backbone And C-Terminal Modifications | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2012-07-12 | — | — | US | disclosed |
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| CN-1164232-A | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LTD (GB) | 1997-11-05 | — | — | CN | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174079-B2 | Compstatin analogs with improved pharmacokinetic properties | VIP, C1QBP, C9 | ALDH1A1 4874/4885LMNA 1217/4885GAA 3396/4885 |
| US-20190077834-A1 | Compstatin Analogs With Improved Pharmacokinetic Properties | VIP, C1QBP, C9 | ALDH1A1 4874/4885LMNA 1217/4885GAA 3396/4885 |
| US-20210032291-A1 | Compstatin Analogs With Improved Pharmacokinetic Properties | VIP, C1QBP, C9 | ALDH1A1 4874/4885LMNA 1217/4885GAA 3396/4885 |
| US-20120178694-A1 | Modified Compstatin With Peptide Backbone And C-Terminal Modifications | PTMS, C9, C3AR1 | ALDH1A1 4867/4885LMNA 2786/4885GAA 3430/4885 |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | ALDH1A1 1423/4885LMNA 412/4885GAA 4480/4885 |
| US-20170247413-A1 | COMPSTATIN ANALOGS WITH IMPROVED PHARMACOKINETIC PROPERTIES | VIP, C1QBP, C9 | ALDH1A1 4874/4885LMNA 1217/4885GAA 3396/4885 |
| US-10745442-B2 | Compstatin analogs with improved pharmacokinetic properties | VIP, C1QBP, C9 | ALDH1A1 4874/4885LMNA 1217/4885GAA 3396/4885 |
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | CFB, C3AR1, C9 | ALDH1A1 4879/4885LMNA 1453/4885GAA 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.